Trials / Completed
CompletedNCT03445208
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a study of experimental medication BMS-986036 given to healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986036 | Crossover administration to abdomen then upper arm |
Timeline
- Start date
- 2018-02-14
- Primary completion
- 2018-05-02
- Completion
- 2018-05-02
- First posted
- 2018-02-26
- Last updated
- 2020-03-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03445208. Inclusion in this directory is not an endorsement.